Floatz logo

Ketorolac Tromethamine

Cancer

SanofiPhase 2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
65/ 100

Competitive context

151 Active assets in the Cancer cohort.

Asset / SponsorPhaseRating
FENTANYL
M.D. Anderson Cancer Center
Phase 3BB
gsk1120212
Cancer Research UK
Phase 2/3BB
gw786034
University Hospital, Bordeaux
Phase 4BB
PANITUMUMAB
Amgen
Phase 4BB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

Ketorolac Tromethamine is also rated in:

migraine disorderDormant
BBB
Indicative ·
72 / 100
View asset →
Hematological Malignancy (Leukemia- Lymphoma)Dormant
BB
Indicative ·
70 / 100
View asset →
breast cancerDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →